Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Senti Biosciences (SNTI) Cash from Operations (2021 - 2025)

Senti Biosciences has reported Cash from Operations over the past 5 years, most recently at 6875000.0 for Q4 2025.

  • Quarterly results put Cash from Operations at 6875000.0 for Q4 2025, up 49.09% from a year ago — trailing twelve months through Dec 2025 was 43444000.0 (down 4.94% YoY), and the annual figure for FY2025 was 43444000.0, down 4.94%.
  • Cash from Operations for Q4 2025 was 6875000.0 at Senti Biosciences, up from 9446000.0 in the prior quarter.
  • Over the last five years, Cash from Operations for SNTI hit a ceiling of 934675.0 in Q2 2021 and a floor of 16304000.0 in Q1 2023.
  • Median Cash from Operations over the past 5 years was 9446000.0 (2025), compared with a mean of 9223997.26.
  • Biggest five-year swings in Cash from Operations: crashed 868.08% in 2022 and later surged 49.09% in 2025.
  • Senti Biosciences' Cash from Operations stood at 1142247.0 in 2021, then tumbled by 688.45% to 9006000.0 in 2022, then grew by 21.86% to 7037000.0 in 2023, then crashed by 91.9% to 13504000.0 in 2024, then surged by 49.09% to 6875000.0 in 2025.
  • The last three reported values for Cash from Operations were 6875000.0 (Q4 2025), 9446000.0 (Q3 2025), and 13073000.0 (Q2 2025) per Business Quant data.